Fevipiprant

• Description :

  Fevipiprant (QAW039, NVP-QAW039) is s an orally active, selective, reversible prostaglandin D2 (DP2) receptor antagonist with an Kd value of 1.14 nM. Fevipiprant has the potential for the research of bronchial asthma[1][2][3].

• Product Name Alternative :

  QAW039; NVP-QAW039

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  CRTH2 (GPR44) ; Prostaglandin Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Immunology/Inflammation

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/Fevipiprant.html

• Concentration :

  10mM

• Purity :

  99.63

• Solubility :

  DMSO : ≥ 32 mg/mL

• Smiles :

  O=C(O)CC1=C(C)N(CC2=CC=C(S(=O)(C)=O)C=C2C(F)(F)F)C3=NC=CC=C31

• Molecular Formula :

  C19H17F3N2O4S

• Molecular Weight :

  426.41

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Brightling C, et al. The pharmacology of the prostaglandin D2 receptor 2 (DP2) receptor antagonist, fevipiprant. Pulm Pharmacol Ther. 2021 Jun;68:102030.|[2]Lee HY, et al. Blockade of thymic stromal lymphopoietin and CRTH2 attenuates airway inflammation in a murine model of allergic asthma. Korean J Intern Med. 2020 May;35 (3) :619-629. |[3]Weintraub NL, et al. Role of prostaglandin D2 receptors in the pathogenesis of abdominal aortic aneurysm formation. Clin Sci (Lond) . 2022 Mar 18;136 (5) :309-321.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• Isoform :

  DP

• CAS Number :

  [872365-14-5]